Boston Scientific, Watchman FLX
The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...
Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or ...
The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...
The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.
LAAO—performed with the Watchman FLX device (Boston Scientific) at the same time as ablation or in a sequential manner—lowered the risk of bleeding while providing noninferior efficacy in terms of ...
Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...
Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...